While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
In 2015, 193 parties signed the Paris Agreement. In doing so, they agreed to pursue efforts to limit the average global temperature increase to 1.5° Celsius - or 2.7 degrees Fahrenheit -above pre-industrial levels. To be clear, our planet is already 1.1 degrees hotter than it was 150 years ago. But most scientists agree that an increase of just .4 more degrees will drastically change the world. However, it would continue to be livable. Things do get murky, though, as the projections increase above that.
Dr. Jen Caudle, family physician and associate professor at Rowan University, joined Cheddar to break down how people can protect themselves and family amid the uncertainty of the new Omicron COVID-19 variant. Caudle emphasized the importance of getting vaccinated against COVID-19 with so much still uncertain about the pandemic. "We have to remember delta variant is still here in the United States," she said. "We're still losing too many people every single day to this virus."
Jill and Carlo discuss what appears to be the beginning of the end of Roe v. Wade, another victim dies following the school shooting in Michigan, Omicron in the U.S., Trump's Covid chronology and more.
Was it a coincidence that the omicron coronavirus variant evolved in a region with low vaccination rates? Cheddar speaks with epidemiologist Dr. Eric Feigl-Ding on the topic.
Astra founder, chairman, and CEO Chris Kemp spoke to Cheddar's Kristen Scholer about his company's first successful launch into orbit last month, becoming the fastest space company to reach orbit using a privately developed liquid-fueled rocket. He also noted that the company's priority is to "improve life on Earth from space" by rapidly increasing the number of low-orbiting satellites to do everything from connecting people to monitoring weather patterns.
Stocks closed at session lows Wednesday as investors grew skittish over the first reported case of the COVID-19 omicron variant in California. Josh Sailar, Partner at Blue Zone Wealth Advisors, joins Cheddar News' Closing Bell to discuss investor worry over the new variant, the Fed dropping the word 'transitory' to describe inflation and potentially speeding up their asset tapering timeline, 2022 predictions, and more.
As cases of the COVID-19 Omicron variant continue to pop up, including the first U.S. case in California, how will domestic holiday travel be impacted? That part of the travel sector has mostly recovered from the year-long pandemic rout, while business travel continues its slump. But could a new variant bring new lockdowns and domestic restrictions? Clint Henderson, Senior News Editor at The Points Guy, joins Cheddar News' Closing Bell to discuss what the omicron variant means for holiday travel, best practices for passengers traveling through airports, and more.
Over the Thanksgiving holiday, Elon Musk warned SpaceX employees in a leaked email that the company could be forced to file Chapter 11 bankruptcy if its raptor engine program fails. Musk then commented on the previous statement adding the detail that a recession could make such a bankruptcy possible.
